GOLETA, Calif .- (Business Wire)-INOGEN, INC. medical (Tase 🙂 equipment and supply Co. , Ltd. (002223.sz, Yuwell), which is a manufacturer for home health care medical care with a comprehensive set of respiratory products.
It is expected that strategic cooperation in the product portfolio (NASDAQ 🙂 by distributing some respiratory products in the United States and choosing other regions, expanding and strengthening the R&D innovation pipeline, and accelerating the inogen brand to the Chinese market. In addition, Yuwell, through its subsidiary, agreed to invest nearly $ 27.2 million in Inogen, which represents an interest in shares 9.9 %, which enhances cooperation and enhance the Inogen’s public budget.
Cooperation with Yuwell is a pivotal step in accelerating the Inogen growth path. By expanding our product portfolio, global presence and enhancing our innovation pipeline, we expect to be in a good position to capture new opportunities in the market, said Kevin Smith, President and CEO. This cooperation supports our commitment to providing a long -term value to our shareholders and enhances our vision to create Inogen as a platform for the best respiratory solutions in its class for patients all over the world. We are confident that our cooperation with Yuwell will play a decisive role in our continuous success. “
Alex Wu, Chairman of the Yuwell Board of Directors, added that Inogen is a pioneer in the respiratory therapy market, and our strategic cooperation provides both parties to expand its geographical access and meet the needs of the patient all over the world. Yuwell shares Inogen’s commitment to developing and providing innovative and quality products and we believe that together we can make a meaningful difference in the lives of respiratory patients. Together, Yuweell and Inogen aims to determine the next generation of respiratory products.
The cooperation agreement will be effective immediately, while the purchase of shares from Inogen is expected to be closed during the first quarter of 2025, according to some of the usual closing conditions.
About inogen
Inogen, Inc. (NASDAQ: ingn) is a leading company in the field of global medical technology that offers innovative respiratory products to use in the home care environment. Inogen supports the patient’s respiratory care by developing, manufacturing and marketing the best respiratory devices in its category used to provide care for patients with chronic respiratory cases. Inogen partners with patients, prescriptions, home medical equipment presenters, and distributors to make respiratory products widely available, giving patients an opportunity to manage the effect of their disease.
For more information, please visit www.inogen.com.
Inogen used and intends to continue to use it, the investor relationship site, http://investor.inogen.com/, as a way to detect non -general information of materials and cohesion of its disclosure obligations under the FD regulation.
About yuwell
Since its foundation in 1998, Yuwell has been at the forefront of providing advanced medical devices solutions to enhance patient care and improve home health care all over the world. Yuwell (002223.sz) has made revenue more than a billion US dollars in 2023, and has a wide product portfolio through respiratory therapy, diabetes management, electronic diagnostic products, first aid solutions and rehabilitation, among other areas.
With a fixed commitment to clinical excellence, Yuwell offers high -quality and medically reliable products that enable healthcare professionals to achieve superior results for the patient.
With 9 research and development centers on the latest model and 7 advanced production facilities, the presence of global Yuwell extends over more than 100 countries and supports more than 300,000 health care institutions. Yuwell affects the lives of patients all over the world by bringing professional and easy -to -use medical devices to the home.
Topical data
This press statement contains aspecting data in the meaning intended in the 1995 litigation reform law. All the data contained in this communication are not historical facts, including, but not limited to, data related to Inogen future work plans and market opportunities, Financial expectations, growth strategies, and expected operational results are aspiration. Words like AIMS, believe, expect, plans, expect, woe, intend, capabilities, potential, and similar expressions aimed at identifying aspiration data. The aspiration data is subject to many risks and doubts that can cause actual results materially from the current expected results, including but not limited to, the risks and doubts related to the potential benefits of cooperation between Inogen with Yuwell; Satisfaction with the closing conditions under the stock purchase agreement related to stock investment; The timing of closing investment in stocks; The market acceptance of its products; a race; Its sales, marketing and distribution; Sales, marketing, research and planned development activities; And the risks associated with international operations. To obtain a detailed discussion on these risks and other risks that may affect Inogen and financial performance, please refer to the Department of Risk Factors in its annual report on the 10-k for the period ending on December 31, 2023, its separation report in the model 10-x for the quarter-finished quarter On March 31, 2024, in its other files with the Securities and Exchange Committee. These aspecting phrases speak only from the date of this. Inogen relinquishes any commitment to updating these aspiration data except for what the law may require.
View the source version on Businesswire.com: https://www.businingwire.com/news/home/20250126900450/en/
Source: Inogen, Inc.
https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png
Source link